Effect of chemical modifications on allergenic potency of peanut proteins

Authors

Ramon Bencharitiwong, Icahn School of Medicine at Mount Sinai
Hanneke P. M. van der Kleij, HAL Allergy BV
Stef J. Koppelman, University of Nebraska-LincolnFollow
Anna Nowak-Wegrzyn, Icahn School of Medicine at Mount SinaiFollow

Document Type

Article

Date of this Version

2015

Citation

Allergy Asthma Proc 36:185–191, 2015; doi: 10.2500/aap.2015.36.3840.

Comments

Copyright © 2015, OceanSide Publications, Inc., U.S.A. Used by permission.

Abstract

Background: Modification of native peanut extracts could reduce adverse effects of peanut immunotherapy.

Objective: We sought to compare native and chemically modified crude peanut extract (CPE) and major peanut allergens Ara h 2 and Ara h 6 in a mediator-release assay based on the rat basophilic leukemia (RBL) cell line transfected with human Fce receptor.

Methods: Native Ara h 2/6 was reduced and alkylated (RA), with or without additional glutaraldehyde treatment (RAGA). CPE was reduced and alkylated. Sera of subjects with peanut allergy (16 males; median age 7 years) were used for overnight RBL-passive sensitization. Cells were stimulated with 0.1 pg/mL to 10 ug/mL of peanut. B-N-acetylhexosaminidase release (NHR) was used as a marker of RBL degranulation, expressed as a percentage of total degranulation caused by Triton X.

Results: Median peanut-specific immunoglobulin E was 233 kU_A/L. Nineteen subjects were responders, NHR >/= 10% in the mediator release assay. Responders had reduced NHR by RA and RAGA compared with the native Ara h 2/6. Modification resulted in a later onset of activation by 10- to 100-fold in concentration and a lowering of the maximum release. Modified RA-Ara h 2/6 and RAGA-Ara h 2/6 caused significantly lower maximum mediator release than native Ara h 2/6, at protein concentrations 0.1, 1, and 10 ng/mL (p<0.001, <0.001, and <0.001, respectively, for RA; and <0.001, 0.026, and 0.041, respectively, for RAGA). RA-CPE caused significantly lower maximum NHR than native CPE, at protein concentration 1 ng/mL (p<0.001) and 10 ng/mL (p<0.002). Responders had high rAra h 2 immunoglobulin E (mean, 61.1 kU_A/L; p < 0.001) and higher NHR in mediator release assay to native Ara h 2/6 than CPE, which indicates that Ara h 2/6 were the most relevant peanut allergens in these responders.

Conclusions: Chemical modification of purified native Ara h 2 and Ara h 6 reduced mediator release in an in vitro assay ~ 100-fold, which indicates decreased allergenicity for further development of the alternative candidate for safe peanut immunotherapy.